The Event. Q1 fiscal 2027 numbers landed this morning alongside three items that actually matter: Michael Halstead — former President of Intra-Cellular Therapies — is the permanent CEO, filling a seat that had been interim for roughly six months; a completed drug-drug interaction (DDI) study showed HLP003 did not meaningfully alter plasma levels of any of six CYP450 substrates tested; and the outstanding share count went from 61,984,078 at June 30 to 73,060,172 as of today.
The Reaction. The stock is at $11.99, up +48.0% from $8.10 on July 21 — the day APPROACH enrollment completed. That is a violent re-rate into a quarter with no new efficacy data.
The Reality. Two of my three standing risk flags just got retired. The third — dilution — didn’t get worse in the way I’d been bracing for (no new raise), but it got worse in a way I hadn’t been tracking closely enough: $11.6M of share-based compensation in a single quarter, against $753K in the year-ago period, plus another $15.4M of previously unrecognized comp expense hitting next quarter.
The Receipts
Michael Halstead is the permanent CEO. I have flagged the interim-CEO seat as “the loudest unresolved flag in the thesis” in every update since Cola was fired on April 20. It is now filled — and filled by the former President of Intra-Cellular Therapies, the company behind Caplyta, acquired by Johnson & Johnson for $14.6 billion in 2025. The implication: this is the third consecutive senior hire pulled from a neuropsych asset that got bought. Lewis-Hall (ex-Pfizer CMO, SpringWorks board through a $3.4B Merck KGaA acquisition), Brannan (ex-Karuna CMO, $14B Bristol Myers deal), Kramer (ex-BMS, launched Cobenfy), and now Halstead. Four for four. The M&A-appeal read I upgraded to High in February keeps getting reinforced by hiring pattern rather than by press release.
The DDI study is the quiet win. HLP003 is being developed as an adjunctive treatment — meaning patients stay on their SSRI or SNRI and add HLP003 on top. That design is the whole commercial pitch, and it carries an unglamorous but real risk: if HLP003 inhibits or induces the liver enzymes that metabolize antidepressants, you get unpredictable plasma levels of both drugs and a label full of restrictions. The completed study tested HLP003 against six CYP450 substrates and found no meaningful impact on plasma levels of any of them. Why it matters: combined with the published literature, that supports a low likelihood of pharmacokinetic interaction with the SSRI/SNRI classes patients in APPROACH are actually taking. This is not efficacy data and it will not move the Q4 readout. It is the kind of finding that removes a paragraph of caveats from a future label — and a paragraph of questions from a Big Pharma diligence room.
Cash: $166.4M, burn accelerating. Cash rose from $157.3M to $166.4M, driven by the $50M bought deal at $4.85 that closed June 25. But operating cash burn was $37.1M in the quarter (vs. $29.5M a year ago), and research expense alone hit $30.8M vs. $15.0M — a 105% year-over-year increase driven by running APPROACH, EMBRACE, and EXTEND simultaneously. The math: ~$37M/quarter against $166M is roughly 4.5 quarters. That clears the Q4 readout with room, but it does not fund EMBRACE to completion.
The share count story I underweighted. Common shares outstanding went from 61,984,078 (June 30) to 73,060,172 (today) — an ~18% increase in six weeks. Sources: 7,889,846 shares issued July 1 on RSU vesting, 2,997,248 on pre-funded warrant exercise August 10, 189,000 on warrant exercise. The Q1 income statement carries $11,574K of share-based compensation (vs. $753K in Q1 FY2026), and the filings disclose another $15,425K of previously unrecognized comp expense that will land in the September quarter because RSU vesting was accelerated on July 1. Why it matters: this is non-cash, so it doesn’t touch runway. But it is real dilution, and it is the mechanism by which insiders converted a rising share price into shares. Key management compensation for the quarter was $12,479K vs. $1,229K a year ago — a tenfold increase, almost entirely RSUs and PSUs.
The lock-up crack. Of the 4,033,304 RSU-derived shares that vested July 1, lock-up agreements contained acceleration provisions triggered on August 13 — yesterday — releasing restrictions on 1,916,362 shares. Another 2,116,942 shares remain locked. The implication: roughly 1.9 million previously restricted insider shares became freely tradeable one day before the stock printed $11.99. I am not alleging anything improper — acceleration provisions are typically price- or time-triggered and disclosed in advance. But if you are wondering what supply might meet a rally from here, that’s a candidate.
Decoding the +48%
Three weeks, $8.10 to $11.99, with no efficacy data in between. What’s driving it?
